NORE1A is a Ras senescence effector that controls the apoptotic/senescent balance of p53 via HIPK2

Journal of Cell Biology

Volumn 208, Issue 6, 2015, Pages 777-789

  Donninger, Howard ^a   Calvisi, Diego F ^c   Barnoud, Thibaut ^b   Clark, Jennifer ^a   Lee Schmidt, M ^b   Vos, Michele D ^d   Clark, Geoffrey J ^a  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF GREIFSWALD   (Germany)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; CYCLIN DEPENDENT KINASE INHIBITOR 1; DOXYCYCLINE; HOMEODOMAIN INTERACTING PROTEIN KINASE 2; NORE1A PROTEIN; ONCOPROTEIN; PROTEIN P53; RAS PROTEIN; SHORT HAIRPIN RNA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; CARRIER PROTEIN; HIPK2 PROTEIN, HUMAN; HRAS PROTEIN, HUMAN; MONOMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; PROTEIN P21; PROTEIN SERINE THREONINE KINASE; RASSF5 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL AGING; CELL CYCLE ARREST; CELLULAR DISTRIBUTION; COLONY FORMATION; CONTROLLED STUDY; DELETION MUTANT; DOWN REGULATION; EMBRYO; ENZYME ACTIVITY; EXPRESSION VECTOR; GENE ACTIVATION; GENE INDUCTION; GENETIC ASSOCIATION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; MOUSE; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ACETYLATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; SENESCENCE; TRANSIENT TRANSFECTION; ANIMAL; CARCINOGENESIS; CHLOROCEBUS AETHIOPS; COS 1 CELL LINE; ENZYME STABILITY; HEK293 CELL LINE; HEPG2 CELL LINE; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CARCINOGENESIS; CARRIER PROTEINS; CELL AGING; CERCOPITHECUS AETHIOPS; COS CELLS; ENZYME STABILITY; HEK293 CELLS; HEP G2 CELLS; HUMANS; MONOMERIC GTP-BINDING PROTEINS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS P21(RAS); SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84925357281     PISSN: 00219525     EISSN: 15408140     Source Type: Journal    
DOI: 10.1083/jcb.201408087     Document Type: Article

References (54)

1. Aird, K.M., and R. Zhang. 2013. Detection of senescence-associated heterochromatin foci (SAHF). Methods Mol. Biol. 965:185-196. http://dx.doi.org/10.1007/978-1-62703-239-1_12.
2. Aoyama, Y., J. Avruch, and X.F. Zhang. 2004. Nore1 inhibits tumor cell growth independent of Ras or the MST1/2 kinases. Oncogene. 23:3426-3433. http://dx.doi.org/10.1038/sj.onc.1207486.
3. Avruch, J., D. Zhou, J. Fitamant, N. Bardeesy, F. Mou, and L.R. Barrufet. 2012. Protein kinases of the Hippo pathway: regulation and substrates. Semin. Cell Dev. Biol. 23:770-784. http://dx.doi.org/10.1016/j.semcdb.2012.07.002.
4. Beckerman, R., and C. Prives. 2010. Transcriptional regulation by p53. Cold Spring Harb. Perspect. Biol. 2:a000935. http://dx.doi.org/10.1101/cshperspect.a000935.
5. Bianchi-Smiraglia, A., and M.A. Nikiforov. 2012. Controversial aspects of oncogene-induced senescence. Cell Cycle. 11:4147-4151. http://dx.doi.org/10.4161/cc.22589.
6. Brooks, C.L., and W. Gu. 2011. The impact of acetylation and deacetylation on the p53 pathway. Protein Cell. 2:456-462. http://dx.doi.org/10.1007/s13238-011-1063-9.
7. Caldwell, M.E., G.M. DeNicola, C.P. Martins, M.A. Jacobetz, A. Maitra, R.H. Hruban, and D.A. Tuveson. 2012. Cellular features of senescence during the evolution of human and murine ductal pancreatic cancer. Oncogene. 31:1599-1608. http://dx.doi.org/10.1038/onc.2011.350.
8. Calvisi, D.F., F. Pinna, R. Pellegrino, V. Sanna, M. Sini, L. Daino, M.M. Simile, M.R. De Miglio, M. Frau, M.L. Tomasi, et al. 2008. Ras-driven proliferation and apoptosis signaling during rat liver carcinogenesis is under genetic control. Int. J. Cancer. 123:2057-2064. http://dx.doi.org/10.1002/ijc.23720.
9. Calvisi, D.F., H. Donninger, M.D. Vos, M.J. Birrer, L. Gordon, V. Leaner, and G.J. Clark. 2009. NORE1A tumor suppressor candidate modulates p21CIP1 via p53. Cancer Res. 69:4629-4637. http://dx.doi.org/10.1158/0008-5472.CAN-08-3672.
10. Calzado, M.A., L. De La Vega, E. Munoz, and M.L. Schmitz. 2009. From top to bottom: the two faces of HIPK2 for regulation of the hypoxic response. Cell Cycle. 8:1659-1664. http://dx.doi.org/10.4161/cc.8.11.8597.
11. Campbell, P.M., and C.J. Der. 2004. Oncogenic Ras and its role in tumor cell invasion and metastasis. Semin. Cancer Biol. 14:105-114. http://dx.doi.org/10.1016/j.semcancer.2003.09.015.
12. Carter, S., and K.H. Vousden. 2009. Modifications of p53: competing for the lysines. Curr. Opin. Genet. Dev. 19:18-24. http://dx.doi.org/10.1016/j.gde.2008.11.010.
13. Chen, J., W.O. Lui, M.D. Vos, G.J. Clark, M. Takahashi, J. Schoumans, S.K. Khoo, D. Petillo, T. Lavery, J. Sugimura, et al. 2003. The t(1;3) breakpoint-spanning genes LSAMP and NORE1 are involved in clear cell renal cell carcinomas. Cancer Cell. 4:405-413. http://dx.doi.org/10.1016/S1535-6108(03)00269-1.
14. Chen, X., N. Mitsutake, K. LaPerle, N. Akeno, P. Zanzonico, V.A. Longo, S. Mitsutake, E.T. Kimura, H. Geiger, E. Santos, et al. 2009. Endogenous expression of Hras(G12V) induces developmental defects and neoplasms with copy number imbalances of the oncogene. Proc. Natl. Acad. Sci. USA. 106:7979-7984. http://dx.doi.org/10.1073/pnas.0900343106.
15. Chen, Z., L.C. Trotman, D. Shaffer, H.K. Lin, Z.A. Dotan, M. Niki, J.A. Koutcher, H.I. Scher, T. Ludwig, W. Gerald, et al. 2005. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature. 436:725-730. http://dx.doi.org/10.1038/nature03918.
16. Collado, M., and M. Serrano. 2010. Senescence in tumours: evidence from mice and humans. Nat. Rev. Cancer. 10:51-57. http://dx.doi.org/10.1038/nrc2772.
17. Collado, M., J. Gil, A. Efeyan, C. Guerra, A.J. Schuhmacher, M. Barradas, A. Benguría, A. Zaballos, J.M. Flores, M. Barbacid, et al. 2005. Tumour biology: senescence in premalignant tumours. Nature. 436:642. http://dx.doi.org/10.1038/436642a.
18. Courtois-Cox, S., S.M. Genther Williams, E.E. Reczek, B.W. Johnson, L.T. McGillicuddy, C.M. Johannessen, P.E. Hollstein, M. MacCollin, and K. Cichowski. 2006. A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell. 10:459-472. http://dx.doi.org/10.1016/j.ccr.2006.10.003.
19. Cox, A.D., and C.J. Der. 2003. The dark side of Ras: regulation of apoptosis. Oncogene. 22:8999-9006. http://dx.doi.org/10.1038/sj.onc.1207111.
20. Dimauro, T., and G. David. 2010. Ras-induced senescence and its physiological relevance in cancer. Curr. Cancer Drug Targets. 10:869-876. http://dx.doi.org/10.2174/156800910793357998.
21. Di Stefano, V., C. Rinaldo, A. Sacchi, S. Soddu, and G. D'Orazi. 2004. Homeodomain-interacting protein kinase-2 activity and p53 phosphorylation are critical events for cisplatin-mediated apoptosis. Exp. Cell Res. 293:311-320. http://dx.doi.org/10.1016/j.yexcr.2003.09.032.
22. Di Stefano, V., M. Mattiussi, A. Sacchi, and G. D'Orazi. 2005a. HIPK2 inhibits both MDM2 gene and protein by, respectively, p53-dependent and independent regulations. FEBS Lett. 579:5473-5480. http://dx.doi.org/10.1016/j.febslet.2005.09.008.
23. Di Stefano, V., S. Soddu, A. Sacchi, and G. D'Orazi. 2005b. HIPK2 contributes to PCAF-mediated p53 acetylation and selective transactivation of p21Waf1 after nonapoptotic DNA damage. Oncogene. 24:5431-5442. http://dx.doi.org/10.1038/sj.onc.1208717.
24. Donninger, H., M.D. Vos, and G.J. Clark. 2007. The RASSF1A tumor suppressor. J. Cell Sci. 120:3163-3172. http://dx.doi.org/10.1242/jcs.010389.
25. D'Orazi, G., B. Cecchinelli, T. Bruno, I. Manni, Y. Higashimoto, S. Saito, M. Gostissa, S. Coen, A. Marchetti, G. Del Sal, et al. 2002. Homeodomaininteracting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat. Cell Biol. 4:11-19. http://dx.doi.org/10.1038/ncb714.
26. D'Orazi, G., C. Rinaldo, and S. Soddu. 2012. Updates on HIPK2: a resourceful oncosuppressor for clearing cancer. J. Exp. Clin. Cancer Res. 31:63. http://dx.doi.org/10.1186/1756-9966-31-63.
27. Ellis, C.A., M.D. Vos, H. Howell, T. Vallecorsa, D.W. Fults, and G.J. Clark. 2002. Rig is a novel Ras-related protein and potential neural tumor suppressor. Proc. Natl. Acad. Sci. USA. 99:9876-9881. http://dx.doi.org/10.1073/pnas.142193799.
28. Fausti, F., S. Di Agostino, A. Sacconi, S. Strano, and G. Blandino. 2012. Hippo and rassf1a Pathways: A Growing Affair. Mol. Biol. Int. 2012:307628.
29. Feig, L.A., and R.J. Buchsbaum. 2002. Cell signaling: life or death decisions of ras proteins. Curr. Biol. 12:R259-R261. http://dx.doi.org/10.1016/S0960-9822(02)00787-X.
30. Ferbeyre, G., E. de Stanchina, A.W. Lin, E. Querido, M.E. McCurrach, G.J. Hannon, and S.W. Lowe. 2002. Oncogenic ras and p53 cooperate to induce cellular senescence. Mol. Cell. Biol. 22:3497-3508. http://dx.doi.org/10.1128/MCB.22.10.3497-3508.2002.
31. Gu, B., and W.G. Zhu. 2012. Surf the post-translational modification network of p53 regulation. Int. J. Biol. Sci. 8:672-684. http://dx.doi.org/10.7150/ijbs.4283.
32. Hofmann, T.G., A. Möller, H. Sirma, H. Zentgraf, Y. Taya, W. Dröge, H. Will, and M.L. Schmitz. 2002. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat. Cell Biol. 4:1-10. http://dx.doi.org/10.1038/ncb715.
33. Kennedy, A.L., J.P. Morton, I. Manoharan, D.M. Nelson, N.B. Jamieson, J.S. Pawlikowski, T. McBryan, B. Doyle, C. McKay, K.A. Oien, et al. 2011. Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis. Mol. Cell. 42:36-49. http://dx.doi.org/10.1016/j.molcel.2011.02.020.
34. Khokhlatchev, A., S. Rabizadeh, R. Xavier, M. Nedwidek, T. Chen, X.F. Zhang, B. Seed, and J. Avruch. 2002. Identification of a novel Rasregulated proapoptotic pathway. Curr. Biol. 12:253-265. http://dx.doi.org/10.1016/S0960-9822(02)00683-8.
35. Kuilman, T., C. Michaloglou, W.J. Mooi, and D.S. Peeper. 2010. The essence of senescence. Genes Dev. 24:2463-2479. http://dx.doi.org/10.1101/gad.1971610.
36. Lee, D., S.J. Park, K.S. Sung, J. Park, S.B. Lee, S.Y. Park, H.J. Lee, J.W. Ahn, S.J. Choi, S.G. Lee, et al. 2012. Mdm2 associates with Ras effector NORE1 to induce the degradation of oncoprotein HIPK1. EMBO Rep. 13:163-169. http://dx.doi.org/10.1038/embor.2011.235.
37. Levine, A.J. 1997. p53, the cellular gatekeeper for growth and division. Cell. 88:323-331. http://dx.doi.org/10.1016/S0092-8674(00)81871-1.
38. Lowe, S.W., E. Cepero, and G. Evan. 2004. Intrinsic tumour suppression. Nature. 432:307-315. http://dx.doi.org/10.1038/nature03098.
39. Malumbres, M., and M. Barbacid. 2003. RAS oncogenes: the first 30 years. Nat. Rev. Cancer. 3:459-465. http://dx.doi.org/10.1038/nrc1097.
40. Matallanas, D., D. Romano, F. Al-Mulla, E. O'Neill, W. Al-Ali, P. Crespo, B. Doyle, C. Nixon, O. Sansom, M. Drosten, et al. 2011. Mutant K-Ras activation of the proapoptotic MST2 pathway is antagonized by wild-type K-Ras. Mol. Cell. 44:893-906. http://dx.doi.org/10.1016/j.molcel.2011.10.016.
41. Morton, J.P., P. Timpson, S.A. Karim, R.A. Ridgway, D. Athineos, B. Doyle, N.B. Jamieson, K.A. Oien, A.M. Lowy, V.G. Brunton, et al. 2010. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc. Natl. Acad. Sci. USA. 107:246-251. http://dx.doi.org/10.1073/pnas.0908428107.
42. Overmeyer, J.H., and W.A. Maltese. 2011. Death pathways triggered by activated Ras in cancer cells. Front Biosci (Landmark Ed). 16:1693-1713 (Landmark Ed). http://dx.doi.org/10.2741/3814.
43. Park, J., S.I. Kang, S.Y. Lee, X.F. Zhang, M.S. Kim, L.F. Beers, D.S. Lim, J. Avruch, H.S. Kim, and S.B. Lee. 2010. Tumor suppressor ras association domain family 5 (RASSF5/NORE1) mediates death receptor ligand-induced apoptosis. J. Biol. Chem. 285:35029-35038. http://dx.doi.org/10.1074/jbc.M110.165506.
44. Pearson, M., R. Carbone, C. Sebastiani, M. Cioce, M. Fagioli, S. Saito, Y. Higashimoto, E. Appella, S. Minucci, P.P. Pandolfi, and P.G. Pelicci. 2000. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature. 406:207-210. http://dx.doi.org/10.1038/35021000.
45. Poon, C.L., X. Zhang, J.I. Lin, S.A. Manning, and K.F. Harvey. 2012. Homeodomain-interacting protein kinase regulates Hippo pathwaydependent tissue growth. Curr. Biol. 22:1587-1594. http://dx.doi.org/10.1016/j.cub.2012.06.075.
46. Prieur, A., and D.S. Peeper. 2008. Cellular senescence in vivo: a barrier to tumorigenesis. Curr. Opin. Cell Biol. 20:150-155. http://dx.doi.org/10.1016/j.ceb.2008.01.007.
47. Puca, R., L. Nardinocchi, D. Givol, and G. D'Orazi. 2010. Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells. Oncogene. 29:4378-4387. http://dx.doi.org/10.1038/onc.2010.183.
48. Pylayeva-Gupta, Y., E. Grabocka, and D. Bar-Sagi. 2011. RAS oncogenes: weaving a tumorigenic web. Nat. Rev. Cancer. 11:761-774. http://dx.doi.org/10.1038/nrc3106.
49. Ramirez, R.D., S. Sheridan, L. Girard, M. Sato, Y. Kim, J. Pollack, M. Peyton, Y. Zou, J.M. Kurie, J.M. Dimaio, et al. 2004. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res. 64:9027-9034. http://dx.doi.org/10.1158/0008-5472.CAN-04-3703.
50. Rinaldo, C., A. Prodosmo, F. Siepi, A. Moncada, A. Sacchi, G. Selivanova, and S. Soddu. 2009. HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs nutlin-3 and RITA. Cancer Res. 69:6241-6248. http://dx.doi.org/10.1158/0008-5472.CAN-09-0337.
51. Ringshausen, I., C.C. O'Shea, A.J. Finch, L.B. Swigart, and G.I. Evan. 2006. Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell. 10:501-514. http://dx.doi.org/10.1016/j.ccr.2006.10.010.
52. Schubbert, S., K. Shannon, and G. Bollag. 2007. Hyperactive Ras in developmental disorders and cancer. Nat. Rev. Cancer. 7:295-308. http://dx.doi.org/10.1038/nrc2109.
53. Serrano, M., A.W. Lin, M.E. McCurrach, D. Beach, and S.W. Lowe. 1997. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 88:593-602. http://dx.doi.org/10.1016/S0092-8674(00)81902-9.
54. Studebaker, A.W., G. Storci, J.L. Werbeck, P. Sansone, A.K. Sasser, S. Tavolari, T. Huang, M.W. Chan, F.C. Marini, T.J. Rosol, et al. 2008. Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner. Cancer Res. 68:9087-9095. http://dx.doi.org/10.1158/0008-5472. CAN-08-0400.